A. Agaimy, T. T. Rau, A. Hartmann, and R. Stoehr, SMARCB1 299 (INI1)-negative rhabdoid carcinomas of the gastrointestinal 300 tract: Clinicopathologic and molecular study of a highly ag-301 gressive variant with literature review, Am J Surg Pathol, vol.38, issue.7, pp.910-920, 2014.

A. Agaimy, F. Haller, J. Frohnauer, I. M. Schaefer, and P. Ströbel, , p.304

A. Hartmann, Pancreatic undifferentiated rhabdoid car-305 cinoma: KRAS alterations and SMARCB1 expression status 306 define two subtypes, Mod Pathol, vol.28, issue.2, 2015.

A. Agaimy and W. Weichert, SMARCA4-deficient sinonasal 308 carcinoma, Head Neck Pathol, vol.11, issue.4, 2017.

H. Blons, J. F. Emile, K. L. Malicot, C. Julié, A. Zaanan et al., , p.310

. Tabernero, Prognostic value of KRAS mutations in stage 311 III colon cancer: Post hoc analysis of the PETACC8 phase III 312 trial dataset, Ann Oncol, vol.25, issue.12, 2014.

F. Bourdeaut, D. Lequin, L. Brugières, S. Reynaud, and C. Dufour, , p.314

F. Doz, Frequent hSNF5/INI1 germline mutations in pa-315 tients with rhabdoid tumor, Clin Cancer Res, vol.17, issue.1, pp.316-347, 2011.

B. Brennan, C. Stiller, and F. Bourdeaut, Extracranial rhabdoid 318 tumours: What we have learned so far and future directions, p.319

, Lancet Oncol, vol.14, issue.8, pp.329-336, 2013.

J. Calderaro, J. Masliah-planchon, W. Richer, L. Maillot, and P. , , p.321

L. Maille and . Mansuy, Balanced translocations disrupting 322 SMARCB1 are hallmark recurrent genetic alterations in renal 323 medullary carcinomas, Eur Urol, vol.69, issue.6, pp.1055-1061, 2016.

A. L. Folpe, J. K. Schoolmeester, W. G. Mccluggage, and L. M. , , p.325

K. Sullivan, W. A. Castagna, and . Ahrens, SMARCB1-326 deficient vulvar neoplasms: A clinicopathologic, immunohis-327 tochemical, and molecular genetic study of 14 cases, Am J, p.328

, Surg Pathol, vol.39, issue.6, pp.836-849, 2015.

K. Kohashi, Y. Oda, H. Yamamoto, S. Tamiya, and Y. Oshiro,

. Izumi, SMARCB1/INI1 protein expression in round cell 331 soft tissue sarcomas associated with chromosomal transloca-332 EWS: A special reference to SMARCB1/INI1 333 negative variant extraskeletal myxoid chondrosarcoma, Am J, p.334

, Surg Pathol, vol.32, issue.8, pp.1168-1174, 2008.

J. Masliah-planchon, I. Bièche, J. M. Guinebretière, and F. , Bour-336 deaut and O. Delattre, SWI/SNF chromatin remodeling and 337 human malignancies, Annu Rev Pathol, vol.10, pp.145-171, 2015.

M. Pancione, A. Remo, C. Zanella, L. Sabatino, and A. D. Blasi, , p.339

C. Laudanna, The chromatin remodelling component

, SMARCB1/INI1 influences the metastatic behavior of col-341 orectal cancer through a gene signature mapping to chromo-342 some 22, J Transl Med, vol.11, p.297, 2013.

M. Pancione, A. D. Blasi, L. Sabatino, A. Fucci, and A. M. Dalena, , p.344

N. Palombi, A novel case of rhabdoid colon carcinoma 345 associated with a positive CpG island methylator phenotype 346 and BRAF mutation, Hum Pathol, vol.42, issue.7, pp.1047-1052, 2011.

J. Taieb, J. Tabernero, E. Mini, F. Subtil, G. Folprecht et al.,

. Van-laethem, Oxaliplatin, fluorouracil, and leucovorin 349 with or without cetuximab in patients with resected stage III 350 colon cancer (PETACC-8): An open-label, randomised phase 351 3 trial, Lancet Oncol, vol.15, issue.8, pp.862-873, 2014.

J. Taieb, A. Zaanan, K. L. Malicot, C. Julié, H. Blons et al.,

. Mineur, Prognostic effect of BRAF and KRAS muta-354 tions in patients with stage III colon cancer treated with leu-355 covorin, fluorouracil, and oxaliplatin with or without cetux-356 imab: A post hoc analysis of the PETACC-8 trial, JAMA On-357 col, pp.1-11, 2016.

J. Taieb, K. L. Malicot, Q. Shi, F. Lorca, and O. Bouché, , p.359

J. Tabernero, Prognostic value of BRAF and KRAS mu-360 tations in MSI and MSS stage III colon cancer, J Natl Cancer, vol.361, issue.5, 2017.

A. Tauziède-espariat, J. Masliah-planchon, L. Brugières, and S. , , p.363

C. Puget, P. Dufour, and . Schneider, Deep intronic hotspot 364 variant explaining rhabdoid tumor predisposition syndrome in 365 two patients with atypical teratoid and rhabdoid tumor, Eur J 366 Hum Genet, vol.25, issue.10, pp.1170-1172, 2017.

L. Tóth, Z. Nemes, S. Gomba, L. Asztalos, C. Molnár et al., An-368 drás et al, Primary rhabdoid cancer of the ileum: A case report 369 and review of the literature, Pathol Res Pract, vol.206, issue.2, pp.110-115, 2010.

X. Wang, J. R. Haswell, and C. W. Roberts, Molecular path-372 ways: SWI/SNF (BAF) complexes are frequently mutated in 373 cancer-mechanisms and potential therapeutic insights, Cancer Res, vol.374, issue.1, pp.21-27, 2014.

J. Wang, J. Andrici, L. Sioson, A. Clarkson, A. Sheen et al., Loss of INI1 expression in colorectal carci-377 noma is associated with high tumor grade, poor survival, 378 BRAFV600E mutation, and mismatch repair deficiency, Hum, vol.379, pp.83-90, 2016.

X. Wang, J. R. Haswell, and C. W. Roberts, Molecular path-381 ways: SWI/SNF (BAF) complexes are frequently mutated in 382 cancer-mechanisms and potential therapeutic insights, Cancer Res, vol.383, issue.1, pp.21-27, 2014.

S. Wöhrle, A. Weiss, M. Ito, A. Kauffmann, and M. Murakami, Z, p.385

. Jagani, Fibroblast growth factor receptors as novel ther-386 apeutic targets in SNF5-deleted malignant rhabdoid tumors, p.387

, PloS One, vol.8, issue.10, p.77652, 2013.